Cargando…
MUC1 modulates the tumor immune microenvironment through the engagement of Siglec-9
Siglec-9 is a sialic acid binding lectin predominantly expressed on myeloid cells. Aberrant glycosylation occurs in essentially all types of cancers resulting in increased sialylation. Thus when MUC1 is expressed on cancer cells it is decorated by multiple short, sialylated O-linked glycans (MUC1-ST...
Autores principales: | Beatson, Richard, Tajadura-Ortega, Virginia, Achkova, Daniela, Picco, Gianfranco, Tsourouktsoglou, Theodora-Dorita, Klausing, Sandra, Hillier, Matthew, Maher, John, Noll, Thomas, Crocker, Paul R., Taylor-Papadimitriou, Joyce, Burchell, Joy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5257269/ https://www.ncbi.nlm.nih.gov/pubmed/27595232 http://dx.doi.org/10.1038/ni.3552 |
Ejemplares similares
-
Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas
por: Picco, Gianfranco, et al.
Publicado: (2014) -
Latest developments in MUC1 immunotherapy
por: Taylor-Papadimitriou, Joyce, et al.
Publicado: (2018) -
The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL
por: Beatson, Richard, et al.
Publicado: (2015) -
Interactions between the breast cancer-associated MUC1 mucins and C-type lectin characterized by optical tweezers
por: Hadjialirezaei, Soosan, et al.
Publicado: (2017) -
O-linked mucin-type glycosylation in breast cancer
por: Burchell, Joy M., et al.
Publicado: (2018)